Donepezil Tied to Risk for Overactive Bladder
Risk for overactive bladder varies across individual cholinesterase inhibitor drugs
Overactive Bladder/Enuresis
Outcomes Worse for Hospitalized Patients With Incontinence
Outcomes even worse for hospitalized patients with incontinence who require treatment of incontinence-associated dermatitis
New Drug Product: Gemtesa
This slideshow show drug information for Gemtesa. Click here for the complete Gemtesa monograph.
Gemtesa Now Available for Overactive Bladder Treatment
Gemtesa is an oral, once-daily, small molecule beta-3 adrenergic agonist.
Myrbetriq Approved for Pediatric Neurogenic Detrusor Overactivity
Both formulations are indicated for patients aged 3 years and older; however, the tablet formulation is specifically approved for patients weighing 35kg or more.
Hormone Therapy May Reduce Nocturia After Menopause
Prevalence of nocturia reduced among postmenopausal women who selected systemic hormone therapy compared with no treatment
Adding Vibegron to BPH Meds Safe, Effective for Overactive Bladder
In a small study, add-on vibegron appeared well-tolerated and clinically effective among men with persistent OAB.
Botox Approved for Neurogenic Detrusor Overactivity in Pediatric Patients
The approval is supported by data from a phase 3 study that assessed the efficacy and safety of Botox in patients aged 5 to 17 years with urinary incontinence due to NDO and using clean intermittent catheterization.
Factors Associated With Low Persistence, Adherence to OAB Medication
Researchers conducted meta-analyses to investigate the real rates of persistence and adherence to overactive bladder drug therapies and moderating factors.
Mirabegron Granted Priority Review for Neurogenic Detrusor Overactivity
The submissions are supported by data from a phase 3 study that evaluated mirabegron in 91 patients aged 3 to 17 years with NDO on clean intermittent catheterization.
